A study analyzing the remedies available to target companies in public merger agreements for a buyer's failure to close the transaction because of a breach or financing failure. The study covers all merger agreements entered into in 2012 for debt-financed acquisitions of US, publicly traded companies (excluding REITs) with a deal value of at least $100 million.

The 2013 edition includes detailed analysis of the remedy models, financing covenants and Xerox provisions seen in 2012.